We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Failing to comply with FDA GMPs can have serious financial ramifications for a pharmaceutical firm — a reality that needs to be reflected in the priorities and actions of drug manufacturers’ boardrooms, according to a compliance and quality management expert.